Login Register Cart 0
Generic placeholder image

Current Nanomedicine

Editor-in-Chief

ISSN (Print): 2468-1873
ISSN (Online): 2468-1881

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Nanogel Development and its Importance in Ophthalmic Drug Delivery System

Author(s): Sachin S. Gaikwad*, Sahil V. Jadhav and Kishor S. Salunkhe

Volume 12, Issue 3, 2022

Published on: 04 October, 2022

Page: [204 - 216] Pages: 13

DOI: 10.2174/2468187312666220915150636

Price: $65

Abstract

Background: The current review focuses on ophthalmic nanogels, their applications, their benefits over traditional gels, and the challenges and opportunities of nanogels. The major goal is to investigate ophthalmic nanogels from preparation through characterization and how nanogels are the future of the ophthalmic drug delivery system compared to traditional gels, eye drops, and ointments.

Objective: Because of the ophthalmic bioavailability, delivery to the eye is crucial. The lacrimal fluid in the eye clears the eye surface, and the ocular sight is washed away as a result of this medicine. The limited ocular bioavailability was also due to the different obstacles present. Drug nano-gelling systems are effective in improving ocular bioavailability and corneal permeation time. Nanoparticles abound in these nanogels. Various natural polymers, such as Chitosan and Alginate, and synthetic polymers, such as PLA and PLGA, can be used to make nanogels. The use of nanotechnology improves medicine bioavailability and penetration in the eye. However, nanotechnology has some limits, such as large-scale manufacturing, restricting medicine doses, and so forth.

Conclusion: Nanotechnology offers much clinical potential when it comes to treating eye issues. Although ophthalmic nanogels are suited for effective drug delivery, they must meet several requirements. First, the drug component must be encapsulated adequately in a stable polymer complex. In ocular drug delivery, nanogels are a preferable option since they can improve patient compliance and therapeutic impact. In addition, the nanogel has a faster corneal penetration time and higher bioavailability.

Keywords: Anatomy of eye, conjunctival, nanogel, ocular drug delivery, polymer, ophthalmic drug delivery system.

« Previous Next »
Graphical Abstract

[1]
Steinmetz JD, Bourne RRA, Briant PS, et al. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: The right to sight: An analysis for the global burden of disease study. Lancet Glob Health 2021; 9(2): e144-60.
[http://dx.doi.org/10.1016/S2214-109X(20)30489-7] [PMID: 33275949]
[2]
Kang YK, Im JC, Shin JP, Kim IT, Park DH. Short-term analysis of the residual volume of an eye drop following 23-gauge microincision vitrectomy surgery. Korean J Ophthalmol 2017; 31(5): 439-45.
[http://dx.doi.org/10.3341/kjo.2016.0090] [PMID: 28682023]
[3]
Jünemann AGM. Chorągiewicz T, Ozimek M, Grieb P, Rejdak R. Drug bioavailability from topically applied ocular drops. Does drop size matter? Ophthalmol J 2016; 1(1): 29-35.
[http://dx.doi.org/10.5603/OJ.2016.0005]
[4]
Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J 2010; 12(3): 348-60.
[http://dx.doi.org/10.1208/s12248-010-9183-3] [PMID: 20437123]
[5]
Gorantla S, Rapalli VK, Waghule T, et al. Nanocarriers for ocular drug delivery: Current status and translational opportunity. RSC Advances 2020; 27835-55.
[6]
Cholkar K, Dasari SR, Pal D, Mitra AK. Eye: Anatomy, physiology and barriers to drug delivery. In: Ashim KM, Ed. Ocular Transporters and Receptors: Their Role in Drug Delivery. Sawston, UK: Woodhead Publishing Limited 2013; pp. 1-36.
[http://dx.doi.org/10.1533/9781908818317.1]
[7]
Zhang J, Jiao J, Niu M, et al. Ten years of knowledge of nano-carrier based drug delivery systems in Ophthalmology: Current evidence, challenges, and future prospective. Int J Nanomedicine 2021; 16: 6497-530.
[http://dx.doi.org/10.2147/IJN.S329831] [PMID: 34588777]
[8]
Karan W, Chandan S, Manish G, Nishant T. In situ ocular Gel-A novel approach towards ocular drug delivery. Euro J Biomed 2018; 5(6): 237-44.
[9]
Morrison PWJ, Khutoryanskiy VV. Advances in ophthalmic drug delivery. Ther Deliv 2014; 5(12): 1297-315.
[http://dx.doi.org/10.4155/tde.14.75] [PMID: 25531930]
[10]
Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: An overview. World J Pharmacol 2013; 2(2): 47-64.
[http://dx.doi.org/10.5497/wjp.v2.i2.47] [PMID: 25590022]
[11]
Aldrich DS, Bach CM, Brown W, Chambers W, et al. Ophthalmic Preparations 2013; 39(2): 204-12. http://www.triphasepharmasolutions.com/Resources/USP%20Ophthalmic%20Preparations.pdf
[12]
Nanogel - Wikipedia. Available from: https://en.wikipedia.org/wiki/Nanogel
[13]
Majeed A, Khan NA. Ocular in situ gel: An overview. J Drug Deliv Ther 2019; 9(1): 337-47.
[http://dx.doi.org/10.22270/jddt.v9i1.2231]
[14]
Sandle T. Peer reviewed: Aseptic processing sterile ophthalmic preparations and contamination control. J GXP Compl 2014; 18: 1-5.
[15]
Raquez JM, Habibi Y, Murariu M, Dubois P. Polylactide (PLA)-based nanocomposites. Prog Polym Sci 2013; 38(10-11): 1504-42.
[http://dx.doi.org/10.1016/j.progpolymsci.2013.05.014]
[16]
Makadia HK, Siegel SJ. Poly Lactic-co-Glycolic Acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel) 2011; 3(3): 1377-97.
[http://dx.doi.org/10.3390/polym3031377] [PMID: 22577513]
[17]
Fuoco T, Finne-Wistrand A. Enhancing the properties of Poly(ε-caprolactone) by simple and effective random copolymerization of ε-caprolactone with p -dioxanone. Biomacromolecules 2019; 20(8): 3171-80.
[http://dx.doi.org/10.1021/acs.biomac.9b00745] [PMID: 31268691]
[18]
Thakral S, Thakral NK, Majumdar DK. Eudragit®: A technology evaluation. Expert Opin Drug Deliv 2013; 10(1): 131-49.
[http://dx.doi.org/10.1517/17425247.2013.736962] [PMID: 23102011]
[19]
Muxika A, Etxabide A, Uranga J, Guerrero P, de la Caba K. Chitosan as a bioactive polymer: Processing, properties and applications. Int J Biol Macromol 2017; 105(Pt 2): 1358-68.
[http://dx.doi.org/10.1016/j.ijbiomac.2017.07.087] [PMID: 28735006]
[20]
Liu Z, Li J, Nie S, Liu H, Ding P, Pan W. Study of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin. Int J Pharm 2006; 315(1-2): 12-7.
[http://dx.doi.org/10.1016/j.ijpharm.2006.01.029] [PMID: 16616442]
[21]
Retinitis Pigmentosa National Eye Institute. Available from: https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/retinitis-pigmentosa
[22]
Sharma A, Garg T, Aman A, et al. Nanogel-An advanced drug delivery tool: Current and future. Artif Cells Nanomed Biotechnol 2016; 44(1): 165-77.
[http://dx.doi.org/10.3109/21691401.2014.930745] [PMID: 25053442]
[23]
Zarekar NS, Lingayat VJ, Pande Vv. Nanogel as a novel platform for smart drug delivery system. Nanosci Nanotechnol Res 2017; 4(1): 25-31.
[24]
Kendre PN, Satav TS. Current trends and concepts in the design and development of nanogel carrier systems. Polym Bull 2019; 76(3): 1595-617.
[http://dx.doi.org/10.1007/s00289-018-2430-y]
[25]
Hiroo N. Ophthalmic composition with regulated viscosity. US 6,511,949 B1 2003.
[26]
Kokare C, Laddha U. Formulation and evaluation of poloxamer- 407 and hpmc k 15 m based thermosensitive sol-gel transition system of dorzolamide hydrochloride. 355808, 2021.
[27]
Phil G, James E, Lee E, Smith J. Methods and apparatus for manufacturing plasma based plastics and bioplastic produced. US 2015/0268193, 2015.
[28]
Laddha UD, Kshirsagar SJ. Formulation of nanoparticles loaded in situ gel for treatment of dry eye disease: In vitro, ex vivo and in vivo evidences. J Drug Deliv Sci Technol 2021; 61: 102112.
[http://dx.doi.org/10.1016/j.jddst.2020.102112]
[29]
Bonferoni MC, Rossi S, Ferrari F, Caramella C. A modified Franz diffusion cell for simultaneous assessment of drug release and washability of mucoadhesive gels. Pharm Dev Technol 1999; 4(1): 45-53.
[http://dx.doi.org/10.1080/10837459908984223] [PMID: 10027212]
[30]
Laddha UD, Kshirsagar SJ. Formulation of PPAR-gamma agonist as surface modified PLGA nanoparticles for non-invasive treatment of diabetic retinopathy: In vitro and in vivo evidences. Heliyon 2020; 6(8): e04589.
[http://dx.doi.org/10.1016/j.heliyon.2020.e04589] [PMID: 32832706]
[31]
S S, S V, Kumars S. Sterility testing procedure of ophthalmic ocusert aciclovir used for treating herpes simplex virus. Asian J Pharm Clin Res 2017; 10(10): 344-6.
[http://dx.doi.org/10.22159/ajpcr.2017.v10i10.19216]
[32]
Sasaki H, Nagano T, Yamamura K, Nishida K, Nakamura J. Ophthalmic preservatives as absorption promoters for ocular drug delivery. J Pharm Pharmacol 2011; 47(9): 703-7.
[http://dx.doi.org/10.1111/j.2042-7158.1995.tb06726.x] [PMID: 8583378]
[33]
Jain GK, Pathan SA, Akhter S, et al. Microscopic and spectroscopic evaluation of novel PLGA–chitosan Nanoplexes as an ocular delivery system. Colloids Surf B Biointerfaces 2011; 82(2): 397-403.
[http://dx.doi.org/10.1016/j.colsurfb.2010.09.010] [PMID: 20940097]
[34]
Baranowski P, Karolewicz B, Gajda M, Pluta J. Ophthalmic drug dosage forms: Characterisation and research methods. ScientificWorldJournal 2014; 2014: 1-14.
[http://dx.doi.org/10.1155/2014/861904] [PMID: 24772038]
[35]
Jain S, Ancheria RK, Shrivastava S, Soni SL, Sharma M. An overview of nanogel-Novel drug delivery system. Asian J Pharm Res Develop 2019; 7(2): 47-55.
[http://dx.doi.org/10.22270/ajprd.v7i2.482]
[36]
Cabrera FJ, Wang DC, Reddy K, Acharya G, Shin CS. Challenges and opportunities for drug delivery to the posterior of the eye. Drug Discov Today 2019; 1679-84.
[37]
Gote V, Sikder S, Sicotte J, Pal D. Ocular drug delivery: Present innovations and future challenges. J Pharmacol Exp Ther 2019; 602-24.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy